BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of BUCYE conditioning regimens in primary central nervous system lymphoma undergoing autologous hematopoietic stem cell transplantation.

Clinical Trial Description

The prognosis of patients with primary central nervous system lymphoma (PCNSL) is poor. Recent studies have demonstrated that autologous hematopoietic stem cell transplantation (auto-HSCT) could improve the prognosis of these patients. However, the optimal conditioning regimen of auto-HSCT remains unclear. In this study, the investigators evaluated the safety and efficacy of BUCYE conditioning regimens in PCNSL undergoing auto-HSCT. ;

Study Design

Related Conditions & MeSH terms

Autologous Hematopoietic Stem Cell Transplantation
Conditioning
Lymphoma
Primary Central Nervous System Lymphoma

Clinical Trial Details

NCT number	NCT03733327
Study type	Interventional
Source	Nanfang Hospital of Southern Medical University
Contact	Qifa Liu
Phone	+862061641611
Email	liuqifa628@163.com
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	November 2018
Completion date	October 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04083066` - Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma	Phase 4
Active, not recruiting	`NCT02313389` - Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma	Phase 3
Recruiting	`NCT02657785` - Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy	Phase 2/Phase 3
Recruiting	`NCT02836158` - Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL	Phase 2/Phase 3
Recruiting	`NCT06445257` - A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL	N/A
Recruiting	`NCT05135858` - Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma	Phase 1
Completed	`NCT01421524` - Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma	Phase 1
Active, not recruiting	`NCT00863460` - Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients	Phase 2
Active, not recruiting	`NCT05036577` - A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL	Phase 1
Recruiting	`NCT04514393` - Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma	Phase 2
Not yet recruiting	`NCT04066920` - IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL	Phase 2
Recruiting	`NCT00455286` - a Phase II Study in Primary Central Nervous System Lymphoma	Phase 2
Completed	`NCT02301364` - Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)	Phase 2
Completed	`NCT00112593` - Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	N/A
Completed	`NCT02669511` - PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma	Phase 2
Not yet recruiting	`NCT04457869` - A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)	Phase 2
Recruiting	`NCT02655744` - Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute
Recruiting	`NCT02399189` - MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma	Phase 2
Recruiting	`NCT04831658` - A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma	Phase 1/Phase 2
Recruiting	`NCT04899427` - Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma	Phase 2